Journal
JOURNAL OF INTENSIVE CARE
Volume 2, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/s40560-014-0047-2
Keywords
Diffuse alveolar hemorrhage; DAH (recombinant activated factor VII); Systemic lupus erythematosus (SLE)
Categories
Ask authors/readers for more resources
Diffuse alveolar hemorrhage (DAH) is a serious pulmonary complication in patients with autoimmune diseases who are undergoing chemotherapy or have had hematopoietic stem cell transplantation. The use of recombinant factor VIIa (rFVIIa) to treat the acute phase of DAH by endobronchial bronchoscopy has been shown to have a significant clinical impact on the survival and evolution of these patients. We report a clinical case of a patient with DAH secondary to systemic lupus erythematosus (SLE) who was treated with rFVIIa administered using a jet nebulizer, obtaining an adequate hemostatic effect with immediate control of DAH and a significant improvement in gas exchange.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available